Miguel Tejada was also linked to Biogenesis

11 Comments

Royals infielder Miguel Tejada was handed a 105-game suspension from MLB over the weekend following multiple positive tests for amphetamine use, but Pedro Gomez of ESPN.com reports that the former American League MVP was also implicated in the recent Biogenesis investigation. In fact, it appears MLB leveraged his link to Biogenesis to get him to drop an appeal on his 105-game suspension.

Major League Baseball had the choice of going after the 2002 American League MVP for the Biogenesis case, as the league did 13 other players earlier this month, or for the amphetamine case. MLB chose to suspend Tejada after he tested positive for a third time in his career for amphetamines.

Tejada, according to a source familiar with the case, was given the choice of either accepting the 105-game suspension for amphetamine use or facing additional punishment for his Biogenesis connection. Tejada was allegedly a customer of Tony Bosch’s shuttered clinic, which is at the heart of baseball’s recent rash of suspensions. Bosch supplied evidence that Tejada had been a Biogenesis customer.

Tejada has been linked to performance-enhancing drugs dating back to the Mitchell Report and plead guilty to misleading Congress back in 2009. He admitted to purchasing human growth hormone (HGH) in the past, but claimed that he threw the drugs away before injecting them. It’s not clear what he may have purchased from Biogenesis, but any denials are going to ring pretty hollow at this point.

The Royals recently moved Tejada to the 60-day disabled list following a calf strain, so his season was essentially over anyway, but the suspension will also knock him out of commission for the first 64 games in 2014. The 39-year-old has insisted that he doesn’t plan to retire, but there’s a real chance that we have seen the last of him in the majors.

Phillies sign Francisco Liriano and Neil Walker to minor league deals

Francisco Liriano
Jim McIsaac/Getty Images
1 Comment

Robert Murray and MLB.com’s Mark Feinsand reported earlier, respectively, that the Phillies signed pitcher Francisco Liriano and infielder Neil Walker to minor league contracts. If he makes the major league roster, Liriano will earn a salary of $1.5 million with an additional $1.25 million available through performance incentives. Walker’s contract information is not yet known.

Liriano, 36, struggled from 2016-18 but enjoyed a productive year out of the bullpen for the Pirates this past season. He posted a 3.47 ERA with 63 strikeouts and 35 walks over 70 innings. The lefty was quite effective against same-handed batters, limiting fellow lefties to a .659 OPS. That would figure to be a key component if Liriano makes the Phillies’ Opening Day roster.

Walker, 34, hit .261/.344/.395 with eight home runs and 38 RBI over 381 plate appearances with the Marlins last year. The veteran is versastile, having played first, second, and third base along with both corner outfield spots in recent seasons. Despite Walker’s versatility, it is tough to see room on the Phillies’ roster for him, barring injuries to other players. It never hurts to have depth.